AL AMYLOIDOSIS UPFRONT TREATMENT AND CURRENT AND FUTURE STUDIES

AL AMYLOIDOSIS UPFRONT TREATMENT AND CURRENT AND FUTURE STUDIES

Bibliographic Details
Main Author:	E. Kastritis
Format:	Article
Language:	English
Published:	Wiley 2023-05-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000936064.38212.60

Similar Items

Future Developments in the Treatment of AL Amyloidosis
by: Foteini Theodorakakou, et al.
Published: (2022-02-01)

Systemic AL Amyloidosis: Current Approaches to Diagnosis and Management
by: Despina Fotiou, et al.
Published: (2020-08-01)

Current treatment of AL amyloidosis
by: Giovanni Palladini, et al.
Published: (2009-08-01)

Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome
by: Maria Gavriatopoulou, et al.
Published: (2020-06-01)

De Novo AL Amyloidosis in Renal Allograft and Anti-CD38 Monoclonal Antibody Treatment
by: Despina Fotiou, et al.
Published: (2021-12-01)

Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone
by: Efstathios Kastritis, et al.
Published: (2007-10-01)

Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis
by: Foteini Theodorakakou, et al.
Published: (2021-11-01)

Stringent patient selection improves outcomes in systemic light-chain amyloidosis after autologous stem cell transplantation in the upfront and relapsed setting
by: Christopher P. Venner, et al.
Published: (2014-12-01)

CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma—Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance
by: Anja Seckinger, et al.
Published: (2018-07-01)

CMR in AL Amyloidosis and Sarcoidosis. Do Look for Splenic Involvement
by: Niki Lama, MD, et al.
Published: (2024-01-01)

Treatment Options For Relapsed/refractory Systemic Light-Chain (AL) Amyloidosis: Current Perspectives
by: Sarosiek S, et al.
Published: (2019-10-01)

AL Amyloidosis
by: Desport Estelle, et al.
Published: (2012-08-01)

DEBATE UPFRONT vs DELAYED TRANSPLANT
by: F. Gay
Published: (2023-05-01)

SUBCUTANEOUS DARATUMUMAB + BORTEZOMIB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE (VCD) IN PATIENTS WITH NEWLY DIAGNOSED LIGHT CHAIN (AL) AMYLOIDOSIS: UPDATED RESULTS FROM THE PHASE 3 ANDROMEDA STUDY
by: EQ Crusoe, et al.
Published: (2021-10-01)

Bortezomib in the treatment of AL amyloidosis: targeted therapy?
by: Roberto Sitia, et al.
Published: (2007-10-01)

Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis
by: Giovanni Palladini, et al.
Published: (2021-03-01)

A RARE PRESENTATION OF SYSTEMIC AL AMYLOIDOSIS; PULMONARY AL AMYLOIDOSIS
by: Simge ERDEM, et al.
Published: (2022-10-01)

Running chromosome analysis in leukemia or not, upfront or later?
by: Yanming Zhang
Published: (2025-02-01)

Upfront radiotherapy for diffuse lymphangiomatosis in a child
by: Abhishek Purkayastha, et al.
Published: (2016-01-01)

AA amyloidosis: basic knowledge, unmet needs and future treatments
by: Laura Obici, et al.
Published: (2012-05-01)

Advances in Treatment of ATTRv Amyloidosis: State of the Art and Future Prospects
by: Massimo Russo, et al.
Published: (2020-12-01)

AL amyloidosis: an overview on diagnosis, staging system, and treatment
by: Sonia Morè, et al.
Published: (2024-05-01)

Short-term Outcomes After Upfront Chemotherapy Followed by Curative Surgery in Metastatic Colon Cancer: A Comparison With Upfront Surgery Patients
by: Myung Hyun Han, et al.
Published: (2019-12-01)

Screening approaches to cardiac amyloidosis in different clinical settings: Current practice and future perspectives
by: Angelo Giuseppe Caponetti, et al.
Published: (2023-03-01)

Transthyretin Amyloidosis Therapies: Guiding the Future
by: Alejandra González-Duarte
Published: (2021-01-01)

Familial amyloidotic polyneuropathy: current and emerging treatment options for transthyretin-mediated amyloidosis
by: Hund E
Published: (2012-06-01)

Clinical outcomes of upfront combination therapy for portopulmonary hypertension
by: Takatoyo Kiko, et al.
Published: (2024-09-01)

Retinitis pigmentosa associated with systemic light chain amyloidosis (AL amyloidosis)
by: Salem Bouomrani, et al.
Published: (2021-04-01)

P914: VENETOCLAX IN RELAPSE/REFRACTORY AL AMYLOIDOSIS- A MULTICENTER INTERNATIONAL RETROSPECTIVE REAL-WORLD STUDY
by: Eyal Lebel, et al.
Published: (2023-08-01)

Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models
by: Ilaria Marrocco, et al.
Published: (2021-03-01)

Eltrombopag Can Achieve Treatment Free Remission as Upfront Therapy for Patient with Immune Thrombocytopenia
by: Khaldun Obeidat, et al.
Published: (2021-04-01)

INNOVATIONS IN AL AMYLOIDOSIS MANAGEMENT
by: Hande Oğul Sücüllü
Published: (2024-12-01)

Evaluating Prognosis in AL Amyloidosis
by: Rodney H. Falk, MD, et al.
Published: (2020-06-01)

AL Amyloidosis for the Cardiologist and Oncologist
by: Ronald M. Witteles, MD, et al.
Published: (2019-09-01)

Treatment of AL amyloidosis in the era of novel immune and cellular therapies
by: Caitlin Sarubbi, et al.
Published: (2024-06-01)

Mechanisms of Organ Damage and Novel Treatment Targets in AL Amyloidosis
by: Francesca Lavatelli
Published: (2022-01-01)

Autologous peripheral hemopoietic cell transplantation in the treatment of AL-amyloidosis
by: Anna Gennad'evna Smirnova, et al.
Published: (2010-10-01)

Upfront surgery is not advantageous compared to more conservative treatments such as observation or medical treatment for patients with desmoid tumors
by: Shinji Tsukamoto, et al.
Published: (2021-01-01)

Expert recommendation from the Swiss Amyloidosis Network (SAN) for systemic AL-amyloidosis
by: Rahel Schwotzer, et al.
Published: (2020-12-01)

New-onset cardiac amyloidosis while in remission from systemic AL amyloidosis
by: Abiodun Idowu, et al.
Published: (2023-02-01)